Incomplete biomarker testing can lead to inappropriate treatment selection
Only 40% of advanced CRC patients get complete guideline-recommended biomarker testing8
6
The number of biomarkers guidelines recommend testing CRC patients for before treatment
Testing for all guideline-recommend biomarkers before starting treatment can help predict which treatment will work and what won’t
MSI*
KRAS
NRAS
BRAF*
NTRK*
ERBB2*
* indicates biomarker with FDA-matched therapy available
Biomarker testing results can predict a poor response to EGFR therapy
If a patient has a mutation in KRAS, NRAS, or BRAF genes, anti-EGFR therapies alone will not work.8
Prevalence of negative predictors to anti-EGFR therapy
Complete-biomarker testing offers advanced CRC patients a chance for longer survival
Cetuximab and encorafenib combination extends survival in patients with a BRAF V600E mutation, who typically respond poorly to standard therapies.17
| Median Overall Survival mo (95%CI) |
Progression-Free Survival mo (95%CI) |
|
|---|---|---|
| BRAF Regimen | 8.4 (7.5-11.0) | 4.2 (3.7-5.4) |
| Control | 5.4 (4.8-6.6) | 1.5 (1.5-1.7) |
| Median Overall Survival mo (95%CI) |
|
|---|---|
| BRAF Regimen | 8.4 (7.5-11.0) |
| Control | 5.4 (4.8-6.6) |
| Progression-Free Survival mo (95%CI) |
|
|---|---|
| BRAF Regimen | 4.2 (3.7-5.4) |
| Control | 1.5 (1.5-1.7) |